103 related articles for article (PubMed ID: 11125173)
21. An ELISA capture assay for the E7 transforming proteins of HPV16 and HPV18.
Selvey LA; Dunn LA; Murray B; Tindle RW; Frazer IH
J Virol Methods; 1992 May; 37(2):119-27. PubMed ID: 1317876
[TBL] [Abstract][Full Text] [Related]
22. Triggering of death receptor apoptotic signaling by human papillomavirus 16 E2 protein in cervical cancer cell lines is mediated by interaction with c-FLIP.
Wang W; Fang Y; Sima N; Li Y; Li W; Li L; Han L; Liao S; Han Z; Gao Q; Li K; Deng D; Meng L; Zhou J; Wang S; Ma D
Apoptosis; 2011 Jan; 16(1):55-66. PubMed ID: 20882347
[TBL] [Abstract][Full Text] [Related]
23. Systemic delivery of siRNA by actively targeted polyion complex micelles for silencing the E6 and E7 human papillomavirus oncogenes.
Nishida H; Matsumoto Y; Kawana K; Christie RJ; Naito M; Kim BS; Toh K; Min HS; Yi Y; Matsumoto Y; Kim HJ; Miyata K; Taguchi A; Tomio K; Yamashita A; Inoue T; Nakamura H; Fujimoto A; Sato M; Yoshida M; Adachi K; Arimoto T; Wada-Hiraike O; Oda K; Nagamatsu T; Nishiyama N; Kataoka K; Osuga Y; Fujii T
J Control Release; 2016 Jun; 231():29-37. PubMed ID: 26979870
[TBL] [Abstract][Full Text] [Related]
24. Role of the retinoblastoma pathway in senescence triggered by repression of the human papillomavirus E7 protein in cervical carcinoma cells.
Psyrri A; DeFilippis RA; Edwards AP; Yates KE; Manuelidis L; DiMaio D
Cancer Res; 2004 May; 64(9):3079-86. PubMed ID: 15126344
[TBL] [Abstract][Full Text] [Related]
25. Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope.
Alexander M; Salgaller ML; Celis E; Sette A; Barnes WA; Rosenberg SA; Steller MA
Am J Obstet Gynecol; 1996 Dec; 175(6):1586-93. PubMed ID: 8987945
[TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor induction of human papillomavirus type 16 E6/E7 MRNA in tumor cells involves two AP-1 binding sites in the viral enhancer.
Peto M; Tolle-Ersü I; Kreysch HG; Klock G
J Gen Virol; 1995 Aug; 76 ( Pt 8)():1945-58. PubMed ID: 7636475
[TBL] [Abstract][Full Text] [Related]
27. Human papillomavirus E7 oncoprotein dysregulates steroid receptor coactivator 1 localization and function.
Baldwin A; Huh KW; Münger K
J Virol; 2006 Jul; 80(13):6669-77. PubMed ID: 16775354
[TBL] [Abstract][Full Text] [Related]
28. Cellular responses of HPV-positive cancer cells to genotoxic anti-cancer agents: repression of E6/E7-oncogene expression and induction of apoptosis.
Butz K; Geisen C; Ullmann A; Spitkovsky D; Hoppe-Seyler F
Int J Cancer; 1996 Nov; 68(4):506-13. PubMed ID: 8945623
[TBL] [Abstract][Full Text] [Related]
29. Herpes simplex virus VP22-human papillomavirus E2 fusion proteins produced in mammalian or bacterial cells enter mammalian cells and induce apoptotic cell death.
Roeder GE; Parish JL; Stern PL; Gaston K
Biotechnol Appl Biochem; 2004 Oct; 40(Pt 2):157-65. PubMed ID: 14709162
[TBL] [Abstract][Full Text] [Related]
30. Tanshinone IIA inhibits viral oncogene expression leading to apoptosis and inhibition of cervical cancer.
Munagala R; Aqil F; Jeyabalan J; Gupta RC
Cancer Lett; 2015 Jan; 356(2 Pt B):536-46. PubMed ID: 25304375
[TBL] [Abstract][Full Text] [Related]
31. Human papillomavirus type 16 expression in cervical keratinocytes: role of progesterone and glucocorticoid hormones.
Mittal R; Tsutsumi K; Pater A; Pater MM
Obstet Gynecol; 1993 Jan; 81(1):5-12. PubMed ID: 8380104
[TBL] [Abstract][Full Text] [Related]
32. Molecular mechanism of carcinogenesis by human papillomavirus-16.
Ishiji T
J Dermatol; 2000 Feb; 27(2):73-86. PubMed ID: 10721654
[TBL] [Abstract][Full Text] [Related]
33. HPV-16 E2 physical status and molecular evolution in vivo in cervical carcinomas.
Kahla S; Kochbati L; Chanoufi MB; Maalej M; Oueslati R
Int J Biol Markers; 2014 Mar; 29(1):e78-85. PubMed ID: 24170557
[TBL] [Abstract][Full Text] [Related]
34. Oncolytic adenovirus armed with human papillomavirus E2 gene in combination with radiation demonstrates synergistic enhancements of antitumor efficacy.
Wang W; Xia X; Wang S; Sima N; Li Y; Han Z; Gao Q; Luo A; Li K; Meng L; Zhou J; Wang C; Shen K; Ma D
Cancer Gene Ther; 2011 Nov; 18(11):825-36. PubMed ID: 21852812
[TBL] [Abstract][Full Text] [Related]
35. Binding of the human papillomavirus type 16 E7 oncoprotein and the adeno-associated virus Rep78 major regulatory protein in vitro and in yeast and the potential for downstream effects.
Hermonat PL; Santin AD; Zhan D
J Hum Virol; 2000; 3(3):113-24. PubMed ID: 10881991
[TBL] [Abstract][Full Text] [Related]
36. Human papillomavirus type 16 E7 binds to the conserved carboxy-terminal region of the TATA box binding protein and this contributes to E7 transforming activity.
Massimi P; Pim D; Banks L
J Gen Virol; 1997 Oct; 78 ( Pt 10)():2607-13. PubMed ID: 9349482
[TBL] [Abstract][Full Text] [Related]
37. Honeybee venom possesses anticancer and antiviral effects by differential inhibition of HPV E6 and E7 expression on cervical cancer cell line.
Kim YW; Chaturvedi PK; Chun SN; Lee YG; Ahn WS
Oncol Rep; 2015 Apr; 33(4):1675-82. PubMed ID: 25633640
[TBL] [Abstract][Full Text] [Related]
38. The role of HPV oncoproteins and cellular factors in maintenance of hTERT expression in cervical carcinoma cells.
Jeong Seo E; Jung Kim H; Jae Lee C; Tae Kang H; Seong Hwang E
Gynecol Oncol; 2004 Jul; 94(1):40-7. PubMed ID: 15262117
[TBL] [Abstract][Full Text] [Related]
39. Both E6 and E7 oncoproteins of human papillomavirus 16 inhibit IL-18-induced IFN-gamma production in human peripheral blood mononuclear and NK cells.
Lee SJ; Cho YS; Cho MC; Shim JH; Lee KA; Ko KK; Choe YK; Park SN; Hoshino T; Kim S; Dinarello CA; Yoon DY
J Immunol; 2001 Jul; 167(1):497-504. PubMed ID: 11418688
[TBL] [Abstract][Full Text] [Related]
40. Anti-estrogenic activities of indole-3-carbinol in cervical cells: implication for prevention of cervical cancer.
Yuan F; Chen DZ; Liu K; Sepkovic DW; Bradlow HL; Auborn K
Anticancer Res; 1999; 19(3A):1673-80. PubMed ID: 10470100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
